Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
The objective is to assess the predictive value of preoperative biochemical markers, expressed as neutrophil-to-lymphocyte ratio (NLR), in patients with unresectable hepatocellular carcinoma (uHCC) receiving a combination of tailored tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) plus transarterial chemoembolization (TACE). A total of 95 patients with uHCC treated with TACE + TKIs + ICIs in our hospital between March 2018 and October 2021 were included in this retrospective study. The prognosis of the patients was analyzed based on NLRs. Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were evaluated. Univariate and multivariate analyses were used to determine factors affecting survival. Patients with a low pretreatment NLR (NLR ≤ 2.22) had significantly longer OS (25.8 months vs. 16.4 months; P = 0.000) and PFS (14.0 months vs. 11.1 months; P = 0.002). In multivariate analysis, two independent factors affecting PFS were identified: hepatitis B virus infection and NLR. Three independent factors affected OS: tumor size, Eastern Cooperative Oncology Group performance, and NLR. All AEs were tolerable, whereas NLR could be suspected as an indicator of immunotherapy-related AEs. A lower pretreatment NLR (≤2.22) might indicate a better prognosis for patients with uHCC treated with TACE + TKIs + ICIs. NLR could provide better guidance for clinicians when evaluating the prognosis of patients with uHCC treated with TACE + TKIs + ICIs and making clinical treatment decisions.
Anti-Cancer Drugs – Wolters Kluwer Health
Published: Jul 17, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.